Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Susan Kelley
AddedFeb 19, 2024
UpdatedMay 31, 2026
Susan Kelley

Susan Kelley

Board Member, Daré Bioscience

The Org

Susan Kelley's Career

Daré Bioscience
Daré Bioscience

San Diego, CA, US

Board Member· Board
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals

Waltham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Susan Kelley's Career

Daré Bioscience
Daré Bioscience
Public$22.1M332005San Diego, CA, US
Board Member· Board

Leadership at Daré Bioscience

Sabrina Martucci JohnsonSabrina Martucci JohnsonBoard Member
William H. RastetterWilliam H. RastetterBoard Member
Jessica GrossmanJessica GrossmanBoard Member
Cheryl Renee BlanchardCheryl Renee BlanchardBoard Member
Roger HawleyRoger HawleyCo-Founder
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
Acquired$1B02003Waltham, MA, US
Board Member· Board

Leadership at Deciphera Pharmaceuticals

Daniel L FlynnDaniel L FlynnBoard Member
Ron SquarerRon SquarerBoard Member
Patricia AllenPatricia AllenBoard Member
Steven L. HoerterSteven L. HoerterCEO
Michael D. TaylorMichael D. TaylorCo-Founder
James A. BristolJames A. BristolBoard Member

Similar to Deciphera Pharmaceuticals

Blueprint MedicinesBlueprint MedicinesCambridge, MA, USCancer Treatmentsest. 2008Blueprint MedicinesCambridge, MA, US · est. 2008

Blueprint Medicines, based in Cambridge, US, develops targeted cancer treatments for genomically defined patients.

Public · $2.4B641
Karyopharm TherapeuticsKaryopharm TherapeuticsNewton, MA, USPharmaceuticalsest. 2008Karyopharm TherapeuticsNewton, MA, US · est. 2008

US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.

Public · $546.7M385
BeOne MedicinesBeOne MedicinesCambridge, MA, USCancer Treatmentsest. 2010BeOne MedicinesCambridge, MA, US · est. 2010

BeiGene, a global biopharmaceutical firm, specializes in developing targeted and immuno-oncology cancer treatments.

Public · $6.8B10k
G1 TherapeuticsG1 TherapeuticsTriangle (historical), NC, USCancer Therapiesest. 2008G1 TherapeuticsTriangle (historical), NC, US · est. 2008

US-based G1 Therapeutics develops innovative treatments for oncology and breast cancer.

Public · $697.4M170

Susan Kelley's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Susan Kelley

Robin SteeleRobin SteeleBoard Member · Alveo TechnologiesWillard DereWillard DereBoard Member · Mersana TherapeuticsDuke LohrDuke LohrBoard Member · DanaherDerek JantzDerek JantzBoard Member · Precision BioSciencesDanny AounDanny AounBoard Member · Dar Group